Adil Daud, MD, on the Importance of Testing Patients with Melanoma for BRAF Mutations

Video

Adil Daud, MD, spoke about the emergence of next-generation sequencing and the importance of testing patients with melanoma for BRAF mutations.

Adil Daud, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center discussed with CancerNetwork the use of next-generation sequencing to not only spot common BRAF mutations but find rarer mutations in patients with melanoma.

Transcription:

It’s an extremely important subject, and in the past people would use the specific BRAF test and that’s what we did too. But I’d say in the last 2-3 years, most centers in the US have switched to using next-generation sequencing, which has the advantage that you can see the BRAF mutation but you can also see some of the uncommon BRAF mutations like V600K, V600D which it’s about 10% of all BRAF mutations are non-V600E which is the one that’s detected by the BRAF test. But then also you can recognize things like NRAS mutations C-KIT mutations and some of the fusions like the ROS1 fusion, ALK fusion that are rare, but are seen sometimes especially in younger people with melanoma or in melanoma that arises in the achiral extremities, those types of melanomas. Also, for uveal melanoma, next gen sequencing can spot GNAQ, GNA11 mutations, BAP1 loss, which straight forward V600E tests won’t do.

I think the downside of NGS is that it takes 2-3 weeks to get the results back and sometimes you really need to get somebody started as soon as possible. I think it’s reasonable in my opinion to start with immunotherapy, given what we’ve just discussed, while you’re waiting for your NGS results and then when you get your NGS results you could decide whether it makes sense to do target therapy or not.

Related Videos
Common adverse effects following treatment with lenvatinib plus pembrolizumab in the phase 3 CLEAR study include diarrhea, hypertension, and fatigue, according to Thomas E. Hutson, DO, PharmD, FACP.
Lenvatinib in combination with pembrolizumab appears to raise no new safety signals in patients with advanced clear cell renal cell carcinoma after 4 years of follow-up in the phase 3 CLEAR study.
According to Thomas E. Hutson, DO, PharmD, FACP, 4-year follow-up data from the phase 3 CLEAR study confirm the maintained benefits of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Rana R. McKay, MD discusses presentations of interest that were presented at the 2023 Kidney Cancer Research Summit, including a discussion on how PET imaging may identify which patients with renal cell carcinoma may respond to immunotherapy.
A better understanding of tumor biology may be necessary for identifying novel non-immunotherapy–based therapeutic strategies for patients with renal cell carcinoma, according to Rana R. McKay, MD.
Probiotics and other agents targeting fatty acid oxidation are also under evaluation as treatment options for patients with renal cell carcinoma, according to Rana R. McKay, MD.
Other angiogenic agents are also under investigation in renal cell carcinoma, according to Rana McKay, MD, who indicates it will be interesting to see how they compare with belzutifan.
Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.
Ritu Salani, MD, highlights the possible benefit of a novel targeted therapy and autologous tumor vaccine in patients with platinum-resistant ovarian cancer, and in the maintenance setting after treatment for platinum-sensitive disease.